Alumis (NASDAQ:ALMS - Get Free Report)'s stock had its "buy" rating reaffirmed by analysts at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They currently have a $15.00 target price on the stock. HC Wainwright's price target suggests a potential upside of 165.96% from the stock's previous close. HC Wainwright also issued estimates for Alumis' Q1 2025 earnings at ($1.29) EPS, Q1 2025 earnings at ($1.07) EPS, Q2 2025 earnings at ($0.81) EPS, Q2 2025 earnings at ($1.00) EPS, Q3 2025 earnings at ($1.01) EPS, Q3 2025 earnings at ($0.79) EPS, Q4 2025 earnings at ($0.78) EPS, Q4 2025 earnings at ($1.01) EPS, FY2025 earnings at ($3.39) EPS and FY2025 earnings at ($4.26) EPS.
A number of other equities research analysts have also issued reports on the company. Oppenheimer started coverage on Alumis in a research note on Thursday, January 30th. They issued an "outperform" rating and a $32.00 target price for the company. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Alumis in a research report on Thursday, March 20th. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $26.00.
Check Out Our Latest Report on ALMS
Alumis Stock Up 20.0 %
Alumis stock traded up $0.94 during trading on Wednesday, reaching $5.64. 1,623,981 shares of the company's stock were exchanged, compared to its average volume of 285,901. The company's 50-day moving average is $5.39 and its two-hundred day moving average is $8.31. Alumis has a 52-week low of $3.18 and a 52-week high of $13.53.
Institutional Trading of Alumis
A number of hedge funds and other institutional investors have recently made changes to their positions in ALMS. Geode Capital Management LLC acquired a new position in Alumis during the 3rd quarter worth $3,266,000. State Street Corp acquired a new position in Alumis in the third quarter worth about $866,000. Charles Schwab Investment Management Inc. bought a new stake in Alumis in the third quarter valued at about $1,160,000. Stifel Financial Corp bought a new position in Alumis during the 3rd quarter worth approximately $931,000. Finally, Barclays PLC acquired a new position in shares of Alumis in the 3rd quarter worth approximately $197,000.
About Alumis
(
Get Free Report)
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
See Also
Before you consider Alumis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alumis wasn't on the list.
While Alumis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
